We next performed survival analysis, which showed that patients in the AML group with high expression of HBA1 had a better prognosis, whereas patients in the AML group with high expression of PREX1, S100A8 and S100A9 had a worse prognosis (Figs. 8A–8D). The gene discussed is S100A9; the disease is acute myeloid leukemia.